Erasmus Schneider

Dr. Erasmus Schneider joined the Wadsworth Center in 1995 as a research scientist when he established an externally funded research program to investigate multidrug resistance of cancer cells. This research resulted in numerous peer-reviewed publications and presentations at major conferences. Over the years he has continued to work in the area of cancer cell drug resistance, expanding into drugs targeting the folate pathway and DNA precursor synthesis. He was a grant reviewer for the American Cancer Society and a member of its Council for Extramural Research.

From 27 to 213 Dr. Schneider was the director of the Center’s Division of Translational Medicine, and in 213 assumed his current role as the Center’s Associate Director for Research and Technology. In that role he is, among other things, overseeing the Center’s scientific core facilities including its clinical Next Generation Sequencing facility, and special public-private partnerships of the Center.

Dr. Schneider is also the section head for Oncology in New York State’s Clinical Laboratory Reference System. In that position he is responsible for the review of laboratory developed tests submitted by NYS permitted laboratories in the area of Oncology. He is particularly interested in the technical and quality control challenges posed by the advanced molecular techniques used for the diagnosis, prognosis and prediction of therapeutic response of cancer.